SOURCE: NY NanoBusiness Alliance, Inc.

September 22, 2009 13:47 ET

Agenda Announced for the 2nd Annual Livingston Healthcare and Life Science Stakeholders Summit Sponsored by NanoBusiness Alliance

NEW YORK, NY--(Marketwire - September 22, 2009) - Today, Scott Livingston, CEO and Founder of Livingston Securities (www.livingstonsecurities.com) announced the agenda for the 2nd Annual Livingston Healthcare and Life Science Stakeholders Summit.

The Summit is being held at:

Lighthouse International
www.lhiconferencecenter.com
111 East 59th Street
New York, NY 10022
212-821-9220

Conference Chair, Mostafa Analoui, PhD, Head of Healthcare and Life Sciences at Livingston Securities, said, "This is a unique and by invitation-only conference that brings together key stakeholders from pharmaceutical, capital investment, business strategy and federal science and regulatory segments. This conference will include three topics, which are among the top global issues for investors currently." Attendance in the conference is limited to assure open and interactive dialogue among participants during the sessions and networking breaks. This is intended to collectively identify key trends, as well as mutual opportunities among participants for deal making.

Invitees include CEOs, CFOs, COOs for a broad range of pharmaceutical, diagnostic, and platform technology companies, a select number of US and International VCs and PEs, along with key policy makers and federal science and regulatory agencies.

TO REGISTER please email Jonathan Mason jonathan@livingstonsecurities.com or call 212-520-8479.

PROGRAM OUTLINE 12:30-5:00pm

INTRODUCTION: Overview and key investment indicators, Mostafa Analoui

SESSION I: Drug Discovery and Development: Early to Mid-Stage Fund Raise and Alliance

--  BJ Bormann, PhD, SVP of Bus Dev & Licensing, Boehringer Ingelheim
    Pharmaceutical
--  Tory Ramaker, Corporate Head of BD, Baxter
--  Bill Burkoth, Director of Venture Capital, Pfizer Inc
--  Misti Ushio, PhD, VP of Harris & Harris Group
--  Eugene Seymour, MD, CEO of Nanoviricides, Inc
    

SESSION II: Diagnostics: Valuation and Future Directions

--  Mark Dente, MD, VP Healthcare Solution at GE Healthcare
--  Gary Fletcher, PhD, Technology R&D, Becton-Dickenson (BD) Diagnostics
--  Jonathan White, MD, Head of R&D at Haemonetics
--  Douglas Fambrough, MD, Managing Partner, Oxford Bioscience Partners
    

SESSION III: Global and Emerging Investment Opportunities

--  Michael Nowak, PhD, Yorkville Partners
--  Alex Engels, PhD, VP BD Development, Global Medication Delivery, Baxter
--  Camilla khevenhueller Borghese, President of ibi, Rome, Italy
--  Drs. Shamsi and Parasanna, Acunova Life Sciences, Inc
    

NETWORKING RECEPTION 5:00-6:00pm

"Scott Livingston's debut conference focusing on Healthcare, Life Science and Nanotechnology was a tremendous success last year," said Vincent Caprio, Vice President and Event Director, NanoBusiness Alliance. "I'm pleased to be working with Scott again this year for his second annual event, which will prove to be of even greater value to all participants and key stakeholders."

About Livingston Securities

Livingston Securities is dedicated to providing corporate finance and strategic advisory services to corporate clients and sales, trading and related services to institutional investors and high net worth individuals who focus on disruptive technologies and their impact on healthcare, energy, infrastructure and other leading sectors of the American and global economy. Our goal is to provide a unique perspective and expertise on investments in nanotechnology and in companies that are commercializing and/or impacted by scientific advances in the emerging field of nanotechnology. Please visit us at www.livingstonsecurities.com.

About The NanoBusiness Alliance

The NanoBusiness Alliance is the industry association for the emerging nanotechnology industry. Through its extensive network of leading startups, Fortune 500 companies, research institutions, non-governmental organizations and public-private partnerships, the Alliance shapes nanotechnology policy and helps accelerate the commercialization of nanotechnology innovations. The NanoBusiness Alliance has offices in Chicago, New York, Connecticut and Washington, DC. For more information, please contact vincentcaprio@nynanobusiness.org or visit us at www.nanobusiness.org.

Contact Information